Beyond Short-Lived Relief: How Arthrosamid Offers Lasting Hope for Knee Osteoarthritis
Arthrosamid, a polyacrylamide hydrogel injectable, offers a promising new treatment for knee osteoarthritis (OA) by providing extended pain relief and improved mobility from a single injection. Unlike traditional hyaluronic acid (HA) injections that require multiple treatments and offer temporary relief lasting a few months, Arthrosamid cushions the joint longer, reducing friction and inflammation for up to two years. Clinical studies demonstrate Arthrosamid’s safety and effectiveness, particularly in patients under 70 with moderate OA. This convenient, cost-effective option may reduce repeated clinic visits and improve patient quality of life. Ongoing research aims to confirm long-term benefits and ideal patient profiles. As a novel, non-surgical approach, Arthrosamid represents an advancement in managing knee OA symptoms, helping patients achieve lasting relief and better joint function.
Targeted Relief for Meniscus-Deficient Knees: How Arthrosamid® Helps Ease Post-Meniscectomy Osteoarthritis Symptoms
Arthrosamid® is a novel single-injection polyacrylamide hydrogel designed to relieve post-meniscectomy osteoarthritis knee pain by cushioning and stabilizing the joint. Unlike traditional treatments providing temporary relief, Arthrosamid® integrates into the synovial membrane, reducing bone-on-bone contact and enhancing knee function. Clinical studies show significant pain reduction and improved mobility lasting up to two years, especially in patients under 70 with moderate OA and normal BMI. The treatment is minimally invasive, well-tolerated, and may delay or prevent the need for surgery. Arthrosamid® offers a promising alternative to hyaluronic acid injections with longer-lasting effects, marking a breakthrough in managing post-meniscectomy knee osteoarthritis.
